Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis

被引：0
|
作者：
Smolen, J. [1 ]
Beaulieu, A. [2 ]
Rubbert-Roth, A. [3 ]
Alecock, E. [4 ]
Alten, R. [5 ]
Woodworth, T. [4 ]
机构：
[1] Univ Clin Internal Med, Clin Dept Pheumatol, Vienna, Austria
[2] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada
[3] Univ Cologne, Med Clin 1, Cologne, Germany
[4] Roche Prod Ltd, Welwyn, SK, Canada
[5] Charite Univ Med Berlin, Schlosspk Clin, Dept Internal Med 2, D-13353 Berlin, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [31] Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis
    Hashimoto, Motomu
    Fujii, Takao
    Hamaguchi, Masahide
    Furu, Moritoshi
    Ito, Hiromu
    Terao, Chikashi
    Yamamoto, Keiichi
    Yamamoto, Wataru
    Matsuo, Takashi
    Mori, Masato
    Ohmura, Koichiro
    Kawabata, Hiroshi
    Mimori, Tsuneyo
    PLOS ONE, 2014, 9 (05):
  • [32] Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs
    Semerano, Luca
    Thiolat, Allan
    Minichiello, Emeline
    Clavel, Gaelle
    Bessis, Natacha
    Boissier, Marie-Christophe
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (07) : 979 - 999
  • [33] The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment
    Butsabong Lerkvaleekul
    Sirisucha Soponkanaporn
    Soamarat Vilaiyuk
    Pediatric Rheumatology, 12 (Suppl 1)
  • [34] Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis
    Hirohata, Shunsei
    Abe, Asami
    Murasawa, Akira
    Kanamono, Toshihisa
    Tomita, Tetsuya
    Yoshikawa, Hideki
    MODERN RHEUMATOLOGY, 2017, 27 (05) : 766 - 772
  • [35] A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis
    Shuntaro Saito
    Katsuya Suzuki
    Keiko Yoshimoto
    Yuko Kaneko
    Yoshihiro Matsumoto
    Kunihiro Yamaoka
    Tsutomu Takeuchi
    Arthritis Research & Therapy, 19
  • [36] A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis
    Saito, Shuntaro
    Suzuki, Katsuya
    Yoshimoto, Keiko
    Kaneko, Yuko
    Matsumoto, Yoshihiro
    Yamaoka, Kunihiro
    Takeuchi, Tsutomu
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [37] IL6 Correlates with Clinical Disease Activity in Patients with Rheumatoid Arthritis
    Milman, Nataliya
    Booth, Ronald
    Karsh, Jacob
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2577 - 2577
  • [38] IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab
    Tanaka, Yoshiya
    Martin Mola, Emilio
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (09) : 1595 - 1597
  • [39] Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity
    van Herwaarden, N.
    Herfkens-Hol, S.
    van der Maas, A.
    van den Bemt, B. J. F.
    van Vollenhoven, R. F.
    Bijlsma, J. W. J.
    den Broeder, A. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (03) : 390 - 394
  • [40] The influence of anti-human IL-6 receptor antibody on bone metabolism in rheumatoid arthritis patients
    Hashimoto, J
    Tsuboi, H
    Yoshikawa, H
    Tomita, T
    Ochi, T
    Yoshizaki, K
    Nishimoto, N
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S216 - S216
12345